Abstracts tagged "Biologicals"

Abstract Number: 1463 • ACR Convergence 2025
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Weibin Bao⁹ and Karl Gaffney¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab, an IL-17A inhibitor, has well-established effectiveness in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA) in both long-term clinical trials and the…
Abstract Number: 1365 • ACR Convergence 2025
Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
Raianni Rúbia Pacheco Silva¹, Daniel da Silva Pereira Curado², Paula Cristina Montina², Everton Nunes da Silva³, Ana Paula Monteiro Gomides², Rina Dalva Neubarth Giorgi⁴, Leticia Rocha Pereira⁵, Sebastião Cezar Radominski⁶, Ivanio Alves Pereira⁷, Maria Fernanda Brandão de Resende Guimarães⁸, Manoel Barros Bertolo⁹, Paulo Louzada Junior¹⁰, Maria de Fátima Lobato da Cunha Sauma¹¹, Karina Rossi Bonfiglioli⁵, Claiton Viegas Brenol¹², Geraldo da Rocha Castelar Pinheiro¹³, Cleandro Pires de Albuquerque² and Licia Maria Henrique da Mota¹⁴, ¹Universidade de Brasília, Brasília, Distrito Federal, Brazil, ²Universidade de Brasília, Brasília, Brazil, ³Universidade de Brasília, brasilia, Brazil, ⁴IAMSPE, São Paulo, Brazil, ⁵Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, ⁶UFPR, Curitiba, Brazil, ⁷UFSC, Florianopolis, Brazil, ⁸UFMG, Belo Horizonte, Brazil, ⁹Unicamp, Campinas, Brazil, ¹⁰USP-RP, Ribeirão Preto, Brazil, ¹¹UFPA, Belem, Brazil, ¹²UFRGS, Porto Alegre, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴UNB, Brasilia, Distrito Federal, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, progressive, potentially disabling autoimmune disease, with substantial economic burden, particularly related to its high-cost pharmacological treatment. Early treatment,…
Abstract Number: 1165 • ACR Convergence 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, Jessica A. Walsh², Timothy P. Fitzgerald³, Soumya Chakravarty⁴, Elizabeth Adamson⁵, Bruno Emond⁶, Carmine Rossi⁷, Samuel Schwartzbein⁷, Kana Yokoji⁷, Yuxi Wang⁷, Patrick Lefebvre⁷, Dominic Pilon⁷, Shikha Singla⁸ and Joseph F Merola⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³Johnson & Johnson, Horsham, PA, USA, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Analysis Group, Inc., Montreal, QC, Canada, QC, ⁷Analysis Group, Inc., Montreal, QC, Canada, QC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: A prior analysis found that patients (pts) with psoriatic arthritis (PsA) treated with guselkumab (GUS), an IL-23p19 subunit inhibitor, were approximately 2× more likely…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: 0886 • ACR Convergence 2025
A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
Patrick Holec, Megan Reitars, Nishant Singh and Isabelle Larsen, Fletcher Biosciences, Cambridge, MA
Background/Purpose: Ankylosing spondylitis (AS), a chronic autoimmune disease strongly associated with HLA-B27:05, is currently managed with therapies that broadly suppress inflammation instead of targeting disease-driving…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…
Abstract Number: 2350 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Upadacitinib (UPA) is a Janus Kinase inhibitor (JAKi) selective for JAK1, approved for the treatment of both Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA).…
Abstract Number: 2130 • ACR Convergence 2025
Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Ashwini Batchu Prithvi, Chaitra Govardhan, Bushra Aladaileh and Athimalaipet V Ramanan, Bristol Royal Hospital for Children, Bristol, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…
Abstract Number: 1612 • ACR Convergence 2025
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug currently approved for the treatment of giant cell arteritis (GCA), regardless of GCA duration. The “window of…
Abstract Number: 1462 • ACR Convergence 2025
Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Kim Hoyt⁹, Weibin Bao¹⁰ and Karl Gaffney¹¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab has demonstrated long-lasting efficacy and a favorable safety profile across multiple clinical trials and domains of psoriatic disease. Real-world data provides additional valuable…
Abstract Number: 1360 • ACR Convergence 2025
Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
Mihye Kwon¹, Chung-il Joung¹ and Young Soo Song², ¹Konyang University Hospital, Daejeon, Republic of Korea, ²Konyang University Hospital, Daejeon, Taejon-jikhalsi, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease in which biologic and targeted synthetic DMARDs (bDMARDs, tsDMARDs) have substantially improved clinical outcomes. While randomized…
Abstract Number: 1160 • ACR Convergence 2025
Plasma Adenosine Deaminase 2 as a Potential Disease Activity Biomarker for Sarcoidosis
Jamie Lim¹, Jayanth Doss², Jeffrey Shen², Rex McCallum², Lisa Carnago³, Hakim Azfar Ali⁴, Ravi Karra⁵, Kees Frelinger², Rishi Rampersad², Susan Kelly², Amanda Eudy⁶, Michael Hershfield⁷ and Teresa Tarrant⁸, ¹Duke University School of Medicine, Durham, NC, ²Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC, ³Division of Rheumatology and Immunology, Duke University Department of Medicine, Duke University School of Nursing, Durham, NC, ⁴Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Department of Medicine, Durham, NC, ⁵Division of Cardiology, Duke University Department of Medicine, Durham, NC, ⁶Duke University, Raleigh, NC, ⁷Division of Rheumatology and Immunology, Duke University Department of Medicine, Department of Biochemistry, Duke University School of Medicine, Durham, NC, ⁸Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham Veterans Administration Hospital, Durham, NC
Background/Purpose: Sarcoidosis is an inflammatory granulomatous disease of unknown etiology that can affect multiple organ systems. There is currently no standardized approach for measuring sarcoidosis…
Abstract Number: 0907 • ACR Convergence 2025
Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
Karel Van Damme¹, Dorine Sichien², Katrien Van der Borght³, Sofie Van Gassen³, Elisabeth De Leeuw³, Victor Bosteels⁴, Joseph Jorssen⁵, Seppe De Winter⁶, Alan Korman⁷, Fabio Benigni⁸, Davide Corti⁸, Ariane Morel⁹, Eric Vivier⁹, Hamida Hammad³, Dirk Elewaut¹⁰, Fabiane Sonego¹¹, Kader Thiam¹¹, Sofie Voet², bianca Balbino¹² and Bart Lambrecht³, ¹Ghent University, Ghent, ²argenx, Ghent, Belgium, ³Ghent University, Ghent, Belgium, ⁴The Francis Crick Institute, London, United Kingdom, ⁵Liège Université, Liege, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Vir Biotechnology, San Francisco, ⁸Vir Biotechnology, Bellinzona, Switzerland, ⁹Innate Pharma, Marseille, France, ¹⁰VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹¹genOway, Lyon, France, ¹²argenx, Gent, Belgium
Background/Purpose: Fc receptors mediate the effector functions of antibodies by linking adaptive and innate immunity. Immunoglobulin G (IgG), the most abundant antibody in circulation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].